BackTELA Bio Overview

TELA Bio Receivables

Latest receivables for TELA: $9.7M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$9.71M
↓ 7.98% YoYΔ $-842000.00 vs prior year quarter

Peer average

Loading

TELA Bio Receivables History

Loading

TELA Bio vs. peers: Receivables Comparison

Loading

TELA Bio Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

TELA Bio (TELA) FAQ

As of the most recent data (March 2026), TELA shows a receivables of $9.7M. That compares with $11M in the prior-year period — down 8.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, TELA's receivables is now $9.7M (was $11M) — a 8.0% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether TELA Bio is outperforming or lagging.

Tracking TELA's receivables over time shows whether TELA Bio is scaling, shrinking, or reshaping that part of the business. The current reading is $9.7M That compares with $11M in the prior-year period — down 8.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has TELA Bio's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $9.7M) with ownership activity and broader fundamentals.

TELA Bio's receivables is $9.7M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.